Failed bioequivalence submissions
Executive Summary
FDA proposes amending its ANDA in vivo bioequivalence regulations to require submission of data "from all BE studies the applicant conducts on a drug product formulation submitted for approval," instead of only those studies meeting the necessary BE criteria. The amended regs will require "all additional passing and nonpassing BE studies conducted" to be submitted "in either a complete or summary report," HHS' Unified Agenda for 2002 says. The advance notice of proposed rulemaking is due out in February. FDA is concerned that submissions often do not include failed BE studies (1"The Pink Sheet" Oct. 23, 2000, p. 25)...
You may also be interested in...
Bioequivalence Studies Reporting Rule Will Boost Submissions By 10% – FDA
A proposed rule to require ANDA sponsors to submit all bioequivalence studies they complete would increase annual BE study reports by 10%, FDA estimates
Failed Bioquivalence Studies Should Accompany ANDAs, FDA's Conner Says
FDA is considering issuing a guidance with instructions for ANDA sponsors on submitting failed bioequivalence studies.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”